Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Terminated 2Recruiting 1

Sponsor Class

OTHER 3NIH 1NETWORK 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3Lymphoid 2Other hematologic neoplasm 1Myeloid 1Genitourinary 1Gastrointestinal 1Classical hematology 1Breast 1

Conditions

Breast Neoplasms 104Neoplasms 13Neoplasm Metastasis 8Sarcoma 6Pancreatic Neoplasms 6Ovarian Neoplasms 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Melanoma 5Leukemia, Myeloid, Acute 5Colorectal Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Squamous Cell Carcinoma of Head and Neck 4Prostatic Neoplasms 4Lung Neoplasms 4Liposarcoma 4Multiple Myeloma 3Head and Neck Neoplasms 3Glioblastoma 3Endometrial Neoplasms 3Colonic Neoplasms 3Breast Diseases 3Brain Neoplasms 3Triple Negative Breast Neoplasms 2Recurrence 2Neoplasm, Residual 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Inflammation 2Estrogen Receptor-positive Breast Cancer 2Esophageal Squamous Cell Carcinoma 2

Interventions

Dexamethasone 420Lenalidomide 265Cyclophosphamide 246Bortezomib 242Melphalan 192Calcium Dobesilate 166fludarabine phosphate 112daratumumab 103Peripheral Blood Stem Cell Transplantation 99carfilzomib 92Thalidomide 90Filgrastim 88Mycophenolic Acid 82fludarabine 81pomalidomide 80Whole-Body Irradiation 80Busulfan 74Tacrolimus 71Granulocyte Colony-Stimulating Factor 66Cyclosporine 58dexamethasone acetate 56ixazomib 55Antilymphocyte Serum 50dexamethasone 21-phosphate 49auricularum 44isatuximab 40Etoposide 39Radiotherapy 36Stem Cell Transplantation 34Methotrexate 33

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Multiple Myeloma × palbociclib × Clear all
NCT02693535 2026-05-29

TAPUR

American Society of Clinical Oncology

Phase 2 Recruiting
4,200 enrolled
LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

OHSU Knight Cancer Institute

Phase 1 Terminated
2 enrolled
BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT02030483 2018-08-22

PD + RD

Weill Medical College of Cornell University

Phase 1 Terminated
9 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡